08:48 AM EDT, 09/19/2024 (MT Newswires) -- Coeptis Therapeutics ( COEP ) said Thursday that it received approval from the Nasdaq Hearings Panel to remain listed on Nasdaq through Jan. 15, 2025.

The company was granted a Nasdaq listing extension after presenting a plan, including a reverse stock split, to address the minimum bid price requirement.

Nasdaq issued a notice of non-compliance with the minimum bid price requirement on Jan. 29, 2024.

Price: 0.2040, Change: +0.03, Percent Change: +16.24